Serratia marcescens strain AH0650_Sm1 is a clinical multidrug-resistant isolate from Australia. Here, we report its annotated draft genome comprising 20 contigs. We identified chromosomal antimicrobial resistance genes including a tet(41) variant, an aac(6=)-Ic variant, ampC, a metallo-beta-lactamase, and several putative multidrug efflux pumps, as well as a novel prophage.
he Gram-negative, facultative anaerobic and motile bacillus Serratia marcescens is an opportunistic human pathogen and a member of the Enterobacteriaceae (1, 2). It is ubiquitous in nature and has been recognized since the 1950s as an etiological agent of nosocomial infections (3), including bacteremia, pneumonia, meningitis, myocarditis, endocarditis, respiratory tract infections, urinary tract infections, and wound infections (4-6). Moreover, S. marcescens can pose a serious obstacle to antimicrobial treatment of infections due to its intrinsic and acquired resistance to a wide range of antimicrobials (7, 8) .
S. marcescens strain AH0650_Sm1 was isolated from the sputum of a pneumonia patient at the Alfred Hospital Intensive Care Unit in Melbourne, Australia, on 20 March 2014. Antimicrobial susceptibility tests via the Vitek 2 system (bioMérieux, France) showed that AH0650_Sm1 was resistant to ampicillin (MIC 16), amoxicillin-clavulanic acid (MIC Ն32), ticarcillin-clavulanic acid (MIC Յ8), piperacillin-tazobactam (MIC Յ4), tobramycin (MIC 4), nitrofurantoin (MIC 256), and cefazolin (MIC Ն64); intermediately resistant to cefoxitin (MIC 16); and susceptible to amikacin (MIC Յ2), ceftriaxone (MIC Յ1), ceftazidime (MIC Յ1), cefepime (MIC Յ1), meropenem (MIC Յ0.25), gentamicin (MIC Յ1), ciprofloxacin (MIC Յ0.25), norfloxacin (MIC Յ0.5), trimethoprim (MIC Յ0.5), and trimethoprim-sulfamethoxazole (MIC Յ20). The unit of all MICs is g/ml.
Whole-genomic DNA was extracted using phenol-chloroform and the Phase Lock Gel protocol (5PRIME), with some minor adaptations, and a barcoded library was prepared using the Nextera XT kit (Illumina, USA). Paired-end sequencing was performed at the Australian Genome Research Facility with the Illumina HiSeq 2500 system, generating 1,858,192 read pairs (2 ϫ 125 bp) yielding 90ϫ coverage. Reads were filtered for an average Phred quality Ն30 and assembled de novo using SPAdes version 3.5.0 (9) with k-mer lengths of 21, 33, 55, 77, and 99. SSPACE version 3.0 (10) was used for scaffolding, and GapFiller version 1.10 (11) was used for filling gaps. Contigs were further extended and reordered using AlignGraph version 27062014 (12) and ABA-CAS version 1.3.1 (13), respectively, with reference to the finished chromosome sequence of S. marcescens Db11 (RefSeq accession no. NZ_HG326223). Contigs shorter than 200 bp were removed. The final assembly was annotated using Prokka version 1.11 (14) . Antimicrobial resistance genes and plasmid replicons were screened using SRST2 (15) with databases from ARG-ANNOT (16) and PlasmidFinder (17) . PHAST (18) was used for identifying prophage regions. These genomic features were further investigated using nucleotide and protein BLAST.
This draft genome contains 5,201,657 bp assembled into 20 contigs with an N 50 of 946 kbp. The genomic annotation includes 4,734 protein coding sequences, 88 tRNA genes, 22 rRNA genes, and one tmRNA gene. Genes related to antimicrobial resistance were identified, including variants of tet(41) and tetR(41) (8) , an aac(6=)-Ic (19) variant, ampC, ampR, and those encoding a metallo-beta-lactamase and several multidrug efflux pumps. A putative novel prophage (31.8 kbp) was identified, which shared 75% identity with Salmonella phage FSL SP-004 (RefSeq GenBank accession no. NC_021774) along 60% of its length. No plasmid replicon was detected.
Nucleotide sequence accession numbers. This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number LFJS00000000. The version described in this paper is the first version, LFJS00000000.1.
